Cargando…

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?

PURPOSE: Adjuvant FOLFOX (5-fluorouracil and oxaliplatin) chemotherapy benefits stage III colon cancer patients. However, it still results in side effects and increased cost. Reducing cycles had been thought to decrease these problems. This retrospective study aimed to find the appropriate number of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Yi-Jian, Lin, Jen-Kou, Chen, Wei-Shone, Jiang, Jeng-Kai, Teng, Hao-Wei, Yen, Chueh-Chuan, Lin, Tzu-chen, Yang, Shung-Haur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980863/ https://www.ncbi.nlm.nih.gov/pubmed/27563513 http://dx.doi.org/10.1186/s40064-016-2976-9

Ejemplares similares

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy
por: Chen, Kuen-Feng, et al.
Publicado: (2015)

The Prognostic Role of Para-Aortic Lymph Nodes in Patients with Colorectal Cancer: Is It Regional or Distant Disease?
por: Lu, Hsueh-Ju, et al.
Publicado: (2015)

The Negative Prognostic Impact of Lymph Node Skip Metastasis in Stage III Colon Cancer With pN1 Disease: A Single-Center and Retrospective Cohort Study
por: Chang, Che-Yuan, et al.
Publicado: (2022)

Patterns of germline and somatic mutations in 16 genes associated with mismatch repair function or containing tandem repeat sequences
por: Chang, Shih‐Ching, et al.
Publicado: (2019)

Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients
por: Lu, Chieh-Sheng, et al.
Publicado: (2016)

Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan
por: Lee, Yu-Ting, et al.
Publicado: (2015)

Differences in gene mutations according to gender among patients with colorectal cancer
por: Tsai, Yi-Jian, et al.
Publicado: (2018)

Impact of LINE-1 hypomethylation on the clinicopathological and molecular features of colorectal cancer patients
por: Kuan, Tai-Chuan, et al.
Publicado: (2018)

Clinicopathological analysis of colorectal carcinoid tumors and patient outcomes
por: Lin, Hung-Hsin, et al.
Publicado: (2014)

Risk factors for delayed perineal wound healing and its impact on prolonged hospital stay after abdominoperineal resection
por: Chang, Chu-Cheng, et al.
Publicado: (2019)

Elevated serum alpha-fetoprotein in poorly differentiated adenocarcinoma with neuroendocrine differentiation of the ascending colon: a case report
por: Lin, Hung-Hsin, et al.
Publicado: (2016)

A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancer
por: Lin, Pei-Ching, et al.
Publicado: (2015)

Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases
por: Liu, Jin-Hwang, et al.
Publicado: (2010)

Building personalized treatment plans for early-stage colorectal cancer patients
por: Lin, Hung-Hsin, et al.
Publicado: (2017)

Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery
por: Yang, Kai-Lin, et al.
Publicado: (2013)

Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer
por: Chang, Chu-Cheng, et al.
Publicado: (2017)

Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma
por: Lan, Yuan-Tzu, et al.
Publicado: (2021)

Clinicopathological and Molecular Features of Patients with Early and Late Recurrence after Curative Surgery for Colorectal Cancer
por: Lan, Yuan-Tzu, et al.
Publicado: (2021)

Clinical relevance of cell-free DNA in gastrointestinal tract malignancy
por: Lan, Yuan-Tzu, et al.
Publicado: (2016)

A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
por: Huang, Sheng-Chieh, et al.
Publicado: (2022)

ER stress‐related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer
por: Liu, Chun‐Yu, et al.
Publicado: (2018)

Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study
por: Li, Shao-Hua, et al.
Publicado: (2023)

Clinicopathological and Molecular Profiles of Sporadic Microsatellite Unstable Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP)
por: Chang, Shih-Ching, et al.
Publicado: (2020)

Prognostic Significance of C-Reactive Protein Polymorphism and KRAS/BRAF in Synchronous Liver Metastasis from Colorectal Cancer
por: Huang, Chi-Jung, et al.
Publicado: (2013)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
por: Zhou, Meijiao, et al.
Publicado: (2022)

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
por: Yang, I-Ping, et al.
Publicado: (2019)

Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women
por: Huang, Chi-Jung, et al.
Publicado: (2016)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
por: Huang, Wen-Yen, et al.
Publicado: (2017)

Three-dimensional versus conventional two-dimensional laparoscopic colectomy for colon cancer: A 3-year follow-up study
por: Yang, Yi-Wen, et al.
Publicado: (2022)

Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway
por: Tsai, Hong-Chieh, et al.
Publicado: (2021)

Author Correction: Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway
por: Tsai, Hong-Chieh, et al.
Publicado: (2021)

Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer
por: Degirmencioglu, Serkan, et al.
Publicado: (2019)

How many steps/day are enough? for adults
por: Tudor-Locke, Catrine, et al.
Publicado: (2011)

How Many Is Enough?—Statistical Principles for Lexicostatistics
por: Zhang, Menghan, et al.
Publicado: (2016)

Melatonin Target Proteins: Too Many or Not Enough?
por: Liu, Lei, et al.
Publicado: (2019)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer
por: Liu, Chun-Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ri7hnvuqovmul2ofogq0ov531i